CStone Pharmaceuticals (HKG:2616) Chief Executive Officer Jianxin Yang increased his holding in the drug company by 560,000 shares, according to a Wednesday filing with the Hong Kong bourse.
Yang purchased the shares at a price ranging from HK$2.26 to HK$3.29 apiece, the filing said.
Since beginning in his role as CEO, Yang has bought 10,359,000 shares, or 5.46% of the total shareholding of CStone.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.